Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

Aspergillose cérébrale : une infection opportuniste émergente chez les patients traités par ibrutinib pour leucémie lymphoïde chronique ?

E Gaye (1) , Audrey Le Bot (2) , Jean-Philippe Talarmin (1) , Ronan Le Calloch (1) , Sorya Belaz (2) , Mathieu Dupont (3) , Pierre Tattevin (2, 4)

1 CH de Quimper
2 CHU Pontchaillou [Rennes]
3 CH de Saint-Malo [Broussais]
4 CIC - Centre d'Investigation Clinique [Rennes]

Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutinib-treated patients. We report two cases of cerebral aspergillosis in CLL patients treated with ibrutinib.

Keywords: Ibrutinib; Chronic lymphocytic leukemia; Cerebral aspergillosis

Keywords: Leucémie lymphoïde chronique; Aspergillose cérébrale; ibrutinib

Domains: Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology; Life Sciences [q-bio]; Cancer; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

E Gaye, Audrey Le Bot, Jean-Philippe Talarmin, Ronan Le Calloch, Sorya Belaz, et al.. Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?. Médecine et Maladies Infectieuses, 2018, 48 (4), pp.294-297. ⟨10.1016/j.medmal.2018.01.003⟩. ⟨hal-01807746⟩